Imotec

Formoterol fumarate, the active ingredient in Imotec, is a long‑acting β2‑adrenergic agonist presented as an inhalation product for inhalation use. It is used for maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD) in adult patients.

GNH USA supplies Imotec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate is a long‑acting bronchodilator that acts on the airway smooth muscle in chronic respiratory diseases.

- Asthma: provides sustained bronchodilation to improve symptom control and reduce exacerbations. - COPD: maintains airway patency, improves lung function and helps prevent flare‑ups. - Bronchospasm: delivers long‑duration relief of bronchial constriction during maintenance therapy.

Formoterol fumarate may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient pain in the head region. - Throat irritation: discomfort or soreness in the throat after inhalation. - Cough: occasional coughing following use of the inhaler.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Arrhythmia: irregular heart rhythm that may require medical attention. - Severe allergic reaction: signs include rash, swelling, or difficulty breathing.

When prescribing Formoterol fumarate, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate patients for existing heart disease before initiation. - Monitor potassium levels: especially in patients on diuretics or with renal impairment. - Use with inhaled corticosteroids: to reduce risk of asthma‑related adverse events. - Avoid abrupt discontinuation: tapering may be needed to prevent loss of control. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Formoterol fumarate can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - MAO inhibitors: increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Theophylline: may enhance stimulant effects on the heart. - Anticholinergics: combined use may increase bronchodilation but also side‑effect risk. - Caffeine: can potentiate tremor and palpitations.